Stock report · Delisted · NYSE
LakeShore Biopharma Co., Ltd (LSBCF)
0.07USD Delisted Final close · Jun 19, 2026
LSBCF no longer trades. LakeShore Biopharma was delisted from the NYSE in June 2026.
All prices on this page are historical. The last trade was on June 19, 2026, at $0.07.
LSBCF stock price history
Final trading statistics
- Final close
- $0.07
- Final trading day
- Jun 19, 2026
- Market cap at delisting
- $2.88M
- Shares outstanding
- 41.21M
- Final 52-week range
- $0.03 – $1.48
- Avg. volume (final 3 mo.)
- 3,713
- All-time high
- $101.40 · Mar 2023
- All-time low
- $0.03 · Apr 2026
- Return since IPO
- -99.3%
- Beta
- 1.01
- Book value / share
- $3.55
- Price / book
- 0.02
About LakeShore Biopharma Co., Ltd
LakeShore Biopharma Co., Ltd was a biopharmaceutical company that discovered, developed, made and sold vaccines and therapeutic biologics for infectious diseases and cancer. Its marketed product was YSJA, a conventional rabies vaccine.
The pipeline included a PIKA rabies vaccine in phase I/III and preclinical studies, and PIKA YS-ON-001, an immuno-oncology candidate in phase I for pancreatic and liver cancer. It also had PIKA YS-HBV-001, a hepatitis B vaccine in phase I, PIKA YS-HBV-002, a preclinical therapy for chronic HBV, and a preclinical PIKA Influenza Vaccine.
Founded in 1994 and based in Beijing, China, it was called YS Biopharma Co., Ltd. until May 2024. Its shares were delisted from the NYSE in June 2026, with a last trade on June 19, 2026 at $0.07.
- Exchange (former)
- NYSE
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Beijing
- Employees
- 758
- IPO date
- August 5, 2021
- Delisted
- June 19, 2026
LakeShore Biopharma Co. financials before the delisting
The last 5 fiscal years LakeShore Biopharma Co. reported as a public company, fiscal year ending March.
LSBCF revenue and net income
LSBCF earnings per share
LSBCF annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $614.96M | −$100.0M | — |
| FY2024 | $573.42M | −$433.5M | −$30.57 |
| FY2023 | $687.20M | −$145.5M | — |
| FY2022 | $502.95M | −$236.7M | −$0.16 |
| FY2021 | $257.02M | −$191.8M | — |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
LakeShore Biopharma Co. stock FAQ
What happened to LakeShore Biopharma Co. stock?
LakeShore Biopharma was delisted from the NYSE in June 2026. The final close was $0.07 on June 19, 2026.
Can I still buy LSBCF stock?
No. LSBCF is no longer listed on the NYSE or any other U.S. exchange; it was removed on June 19, 2026.
What was the last price of LSBCF?
LSBCF last closed at $0.07 on June 19, 2026, which valued the company at about $2.88M.
How did LakeShore Biopharma Co. do in its last full fiscal year?
In fiscal 2025, its last full year as a public company, LakeShore Biopharma Co. reported revenue of $614.96M and net income of −$100.0M.
When did LakeShore Biopharma Co. go public?
LakeShore Biopharma Co. shares started trading on August 5, 2021.
LSBCF no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.